(UroToday.com) In an oral presentation in the New Trials Update session at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Thomas Powles discussed the results of the DANUBE trial, Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer (DANUBE), a front-line randomized, open-label study of durvalumab monotherapy or in combination with tremelimumab versus standard of care chemotherapy in patients with advanced urothelial carcinoma.